title: Valproate therapy does not deplete carnitine levels in otherwise healthy children.
abstract: OBJECTIVE
  To determine whether children with epilepsy undergoing valproate (VPA) antiepileptic therapy and who are otherwise healthy have a lower serum level of carnitine (CAR) and a higher plasma level of plasma ammonia than do normal children.
  
  
  METHODS
  A total of 45 children with epilepsy, 6.3 to 21.7 years of age, who were treated solely with VPA and were free of abnormal neurologic findings or nutritional problems were randomly selected (VPA-treated group). An age-matched control group (n = 45) was selected from subjects without epilepsy (control group). Total (T) and free (F) serum CAR, serum VPA concentration, and the plasma ammonia level were measured and analyzed.
  
  
  RESULTS
  Serum VPA concentration exhibited a weak negative correlation with both T- (r = -0.34) and F-CAR (r = -0.41). The T-CAR levels were 55.7 +/- 12.4 and 57.6 +/- 12.1 mM, and the F-CAR levels 42.7 +/- 9.9 and 44.4 +/- 9.9 mM in the VPA-treated and control groups, respectively. Thus, there was no significant difference in T- or F-CAR levels between the VPA-treated and control groups. Plasma ammonia levels were the same in the two groups: 26 +/- 9.2 and 29.4 +/- 11.8 mM in the VPA-treated and control groups, respectively. There was no significant correlation between blood ammonia and either T- (r = +0.024) or F-CAR (r = -0. 026).
  
  
  CONCLUSIONS
  Children on a regular diet ingest a sufficient amount of CAR that more than meets their daily CAR requirement. The level of neither T- nor F-CAR in patients with epilepsy and without severe neurologic or nutritional problems being treated with VPA appeared to be affected by VPA therapy. Because the blood CAR level depends on nutritional condition rather than on blood VPA concentration, CAR deficiency caused by VPA is not likely to occur in this population. The usefulness of supplementation of CAR for this type of patient with epilepsy, therefore, must be reevaluated carefully.
authors.affiliation: Department of Pediatrics, Fukuoka University, Fukuoka Japan.
authors.forename: S
authors.initials: S
authors.lastname: Hirose
authors.forename: A
authors.initials: A
authors.lastname: Mitsudome
authors.forename: S
authors.initials: S
authors.lastname: Yasumoto
authors.forename: A
authors.initials: A
authors.lastname: Ogawa
authors.forename: Y
authors.initials: Y
authors.lastname: Muta
authors.forename: Y
authors.initials: Y
authors.lastname: Tomoda
mesh_terms: D000293:Adolescent; D000328:Adult; D000641:Ammonia / Q000097:blood; D002331:Carnitine / Q000097:blood*; D016022:Case-Control Studies; D002648:Child; D004827:Epilepsy / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D012016:Reference Values; D014635:Valproic Acid / Q000009:adverse effects* / Q000097:blood
chemical_list: D014635:Valproic Acid; D000641:Ammonia; D002331:Carnitine